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Efficient differentiation of human
embryonic stem cells to retinal pigment
epithelium under defined conditions
Ioannis J. Limnios*, Yu-Qian Chau, Stuart J. Skabo, Denver C. Surrao and Helen C. O’Neill*
Abstract: Age-related macular degeneration (AMD) is a highly prevalent form of blindness caused by loss death of
cells of the retinal pigment epithelium (RPE). Transplantation of pluripotent stem cell (PSC)-derived RPE cells is
considered a promising therapy to regenerate cell function and vision.
Objective: The objective of this study is to develop a rapid directed differentiation method for production of RPE
cells from PSC which is rapid, efficient, and fully defined and produces cells suitable for clinical use.
Design: A protocol for cell growth and differentiation from hESCs was developed to induce differentiation through
screening small molecules which regulated a primary stage of differentiation to the eyefield progenitor, and then, a
subsequent set of molecules to drive differentiation to RPE cells. Methods for cell plating and maintenance have
been optimized to give a homogeneous population of cells in a short 14-day period, followed by a procedure to
support maturation of cell function.
Results: We show here the efficient production of RPE cells from human embryonic stem cells (hESCs) using small
molecules in a feeder-free system using xeno-free/defined medium. Flow cytometry at day 14 showed ~ 90% of
cells expressed the RPE markers MITF and PMEL17. Temporal gene analysis confirmed differentiation through
defined cell intermediates. Mature hESC-RPE cell monolayers exhibited key morphological, molecular, and functional
characteristics of the endogenous RPE.
Conclusion: This study identifies a novel cell differentiation process for rapid and efficient production of retinal RPE
cells directly from hESCs. The described protocol has utility for clinical-grade cell production for human therapy to
treat AMD.
Keywords: Retinal pigment epithelium, Pluripotent stem cells, Differentiation, Small molecules, Age-related macular
degeneration
Introduction
Age-related macular degeneration (AMD) is the most
common cause of blindness in people aged over 60 years
and affects approximately 200 million people worldwide
[1]. While the molecular mechanisms of AMD remain
unclear, growing evidence suggests that metabolic stress
[2] and inflammation [3], in conjunction with risk
factors such as age, genetics, diet, and smoking, play
major roles in disease development [4].
The retinal pigment epithelium (RPE) is the basal layer
of the retina and is required for the survival and func-
tion of photoreceptors. In advanced stages of AMD,
death and/or dysfunction of RPE cells in the macula trig-
ger photoreceptor degeneration, resulting in loss of cen-
tral vision [5].
Early-stage AMD presents as drusen deposits under-
neath the RPE, which then advances to one of two major
forms: wet and dry AMD [6]. Wet AMD accounts for
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10% of cases and is characterized by the uncontrolled
growth of sub-retinal capillaries that can invade through
the Bruch’s membrane to rapidly destroy the RPE and
associated photoreceptors [7]. Standard treatment for
wet AMD is disruption of angiogenic pathways by
monthly intravitreal injections that target the VEGF sig-
naling pathways [8]. Although anti-VEGF therapy can
delay the advancement of wet AMD, 10–15% of patients
is non-responsive or develops tachyphylaxis [9]. Dry
AMD accounts for 90% of AMD cases and is associated
with geographic atrophy of the RPE and retinal degener-
ation in the macula [10]. There is currently no effective
treatment for dry AMD; however, disease onset can be
delayed by dietary supplementation [11].
Cell therapies for AMD aim to halt or reverse disease
progression by sub-retinal transplantation of healthy RPE
cells into the macula to prevent photoreceptor loss and re-
store function [12–14]. Proof-of-concept for RPE trans-
plantation has been established in congenital and injury
models of retinal degeneration in animals, particularly in
the Royal College of Surgeons (RCS) rat [15, 16]. However,
human transplantation studies in AMD using autologous
and non-autologous RPE cells have produced variable and
short-lived benefits [17]. Critical barriers to clinical transla-
tion include patient disease state and progression, surgical
complexity (particularly in autologous transplantation), and
the limited availability and expansion of healthy, functional,
and immune compatible RPE cells [18].
Human pluripotent stem cells (hPSCs) are a poten-
tially unlimited source of RPE cells. Key advantages of
hPSC-derived cell production include genome selection
or editing before differentiation and extensive in vitro
and in vivo quality control of hPSC-derived cell products
prior to human transplantation [19]. Presently, clinical
trials are testing the safety and efficacy of hPSC-RPE cell
transplantation in AMD patients [20].
To date, most clinical trials generate hPSC-RPE cells
by spontaneous differentiation to minimize the risk of
patient exposure to xenogens [20]. However, spontan-
eous differentiation is labor intensive, inefficient, and
highly variable across hPSC lines [21]. Manual enrich-
ment can be improved using RPE-specific antibodies
[22], or lipoprotein uptake [23], followed by cell sorting
using flow cytometry and expansion of cell batches in
culture. Nevertheless, cell batch expansion must be lim-
ited in order to maintain hPSC-RPE cell quality and
function for cell therapy [24].
Directed differentiation protocols can significantly
increase yields in hPSC-RPE cell production [25–29].
However, the most efficient protocols remain incom-
patible with cell therapy due to the use of undefined
animal products [28, 29]. Thus, there remains a need
for a robust and efficient protocol for hPSC-RPE
clinical-grade cell.
Here, we hypothesize that an efficient hESC-RPE cell
differentiation protocol can be developed using small
molecules that recapitulate critical signaling events dur-
ing RPE cell development in vivo. By first determining
an optimal signaling strategy, we then adapt the protocol
to xeno-free defined conditions to demonstrate proof-of-
concept for high differentiation efficiencies using condi-
tions that may be used for commercial scale production
of cells for therapy.
Materials and methods
Human embryonic stem cell culture
MEL-1 hESCs (NIH Registry #0139, passage 29–40;
StemCore, Brisbane, QLD, Australia) were maintained in
mTeSR medium (StemCell Technologies, Vancouver,
BC, Canada) on hESC-qualified Matrigel (MG: Corning
Life Science, Lowell, CA, USA). Cultures were fed daily
and passaged every 5 to 7 days using collagenase IV (1
mg/mL; Gibco, Carlsbad, CA, USA).
Primary fetal RPE cell culture
Human fetal RPE (Φ-RPE) cells (ScienCell Research
Labs: HRPEpiC #6540; Australian Biosearch, Wangarra,
WA, Australia) were thawed and seeded at 50,000 cells/
cm2 in xeno-free/defined RPE Expansion Medium
(XFD-REM) (Table S1) on growth factor reduced Matri-
gel (GFR-MG: BD Biosciences, San Jose, CA, USA) for
one passage. For maturation, cells were dissociated using
TrypLE™ Express (Life Technologies, Melbourne, VIC,
Australia) at day 7 and seeded at 150,000 cells/cm2 on
GFR-MG in XFD-REM (Table S1).
Induction of hESC-RPE differentiation through inhibition
of TGFβ and WNT signaling
hESC colony cultures were incubated with the Rho Kin-
ase inhibitor Y-27632 (Rock Inhibitor, 10 μM: Sigma-
Aldrich, St Louis, MO, USA) for 1 h and dissociated to
single cells using TrypLE™ Express. Cell aggregates
(1000–1500 cells) were formed using the AggreWell™400
system (StemCell Technologies) and cultured in Basal
Differentiation Media (BDM) with Rock inhibitor (Table
S1). For differentiation, aggregates were cultured in
BDM supplemented with combinations of SB43218 (SB:
10 μM), CKI-7 (CKI: 5 μM) and nicotinamide (NIC: 10
mM) (all Sigma-Aldrich). After 6 days, embryoid bodies
(EBs) were plated on GFR-MG-coated plates in BDM.
At day 8, expanding EBs were dissociated with collage-
nase IV (1 mg/mL) and re-plated as clumps of 200 to
500 cells on GFR-MG-coated 24-well dishes. Cells were
then cultured in BDM without factors and refed every 2
to 3 days until day 38.
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Directed two-stage differentiation of hESC-RPE cells using
small molecules
hESCs were dissociated and plated on GFR-MG-coated
10 cm plates at ~ 300,000 cells/cm2 in mTeSR with
10 μM Rock Inhibitor. After reaching 90% confluence,
medium was changed to xeno-free/defined (XFD)-BDM
(Table S1) supplemented with SB (10 μM), LDN193189
(LDN: 100 nM) (Miltentyi Biotec, Sydney, NSW,
Australia), CKI (5 μM), and NIC (10 mM). At day 5, dif-
ferentiating cells were treated with Rock Inhibitor for 1
h, dissociated, and formed into 3D aggregates (~ 1000
cells) termed Anterior Neural Ectodermal Bodies
(ANEBs) using Aggrewells™. ANEBs were cultured in
suspension for 12 h and plated on to 6-well plates coated
with natural mouse laminin (Thermo Fisher Scientific,
Waltham, MA, USA) in XFD-BDM with primary differ-
entiation factors for a further 24 h. Secondary differenti-
ation was initiated on day 7 by changing medium to
XFD-BDM, supplemented with either CHIR99021
(CHIR: 3 μM) and/or IDE-2 (IDE: 250 nM) or LDN + SB
(LDN/SB) until day 16.
Small molecule exclusion assay
To determine the contribution of small molecules to
hESC-RPE cell differentiation at day 14, hESCs were pre-
pared as above, seeded at 100,000 cells/cm2, and grown
for 3 days or until ~ 90% confluent. Differentiation was
initiated as described above with slight modifications,
using combinations of SB, LDN, CKI, and NIC. Aggre-
gates (~ 1200 cells/body) were formed at day 2 and cul-
tured in suspension until day 6 in their respective
primary differentiation conditions. At day 6, aggregates
were plated on Growth Factor-Reduced Matrigel (GFR-
MG; StemCell Technologies) coated 6-well plates.
Twelve hours later, each primary differentiation condi-
tion was changed to one of several secondary differenti-
ation conditions with combinations of IDE, CHIR, and
NIC and cultured until day 14. Optimal differentiation
conditions were determined through morphological ana-
lysis of outgrowths at day 14 and expressed as percent-
age of total cells with early RPE morphology. From day
14, cultures were matured in XFD-BDM (Table S1)
without factors until the appearance of mature, pigmen-
ted, polygonal hESC-RPE cells (day 28).
Xeno-free/defined hESC-RPE cell differentiation
For differentiation under XFD conditions, hESCs were
adapted to mTeSR-E8 medium and then passaged onto
Vitronectin-XF (VXF; StemCell Technologies) with
ReLSR (StemCell Technologies) and differentiated as
ANEBs in XFD-BDM supplemented with SB/LDN/CKI/
NIC (primary differentiation) and IDE/CHIR (secondary
differentiation) on VXF-coated plates.
Expansion and maturation of hESC-RPE cells to epithelial
monolayers
Differentiated hESC-RPE cells were expanded by whole-
dish passage using TrypLE™ Express and plated on either
GFR-MG or VXF at 50,000–100,000 cells/cm2 in XFD-
REM. For maturation of passaged hESC-RPE cells, cells
were plated on to GFR-MG or VXF at 150,000 cells/cm2
in XF-REM supplemented with 10% XFSR and Rock In-
hibitor for 4 days or until confluent. For maturation, the
concentration of XFSR was first reduced to 5% and then
to 2% by day 7, constituting XFD-RPE maturation
medium (XFD-RMM). In some experiments, cells were
grown on GFR-MG-coated culture plates or polyethyl-
ene (PET) Transwell® membranes (Corning, NY, USA).
Cell cryopreservation
hESC cultures were cryopreserved at 50–70% conflu-
ence. Briefly, hESCs were treated with Y-27632 (10 μM,
Rock Inhibitor) for 1 h, cut into small pieces of ~ 100–
300 cells, and resuspended in 1 ml of pre-chilled XF
cryopreservation media (40%XFSR, 50%F12, 10%DMSO)
or L7™hPSC Cryosolution (Lonza, Basel, Switzerland).
Cells were transferred to a freezing container (Nalgene,
Rochester, NY, USA) and slow frozen at −80 °C over-
night before long-term storage in liquid nitrogen.
For hESC-RPE cells and human fetal RPEs, 70–80%
confluent cultures were dissociated using TrypLE™ Ex-
press, counted and cryopreserved at 5 × 106 cells/mL in
XFD cryopreservation media (40% XFSR, 50% DMEM,
10% DMSO), and slow frozen, as described above.
Photomicroscopy
Cell images were captured using Olympus CKX41
Microscope (Olympus Corporation, Centre Valley, PA,
USA) equipped with a Nikon DS-Fil-L2 camera (Nikon
Instruments Inc., Minato City, Tokyo, Japan).
Gene expression analysis
Total RNA was extracted from cells using PureZOL™
RNA Isolation Reagent (BioRad, Hercules, CA, USA) ac-
cording to the manufacturer’s instructions. RNA con-
centration and A260:A280 ratio were quantified using a
NanoDrop 2000c (Thermo Fisher Scientific). One μg of
RNA was reverse transcribed using the iScript™ cDNA
synthesis kit (BioRad), and quantitative PCR analysis
(qPCR) carried out with SsoFast™ EvaGreen® Supermix
(BioRad) using a CFX96 Touch Real-Time PCR machine
(BioRad). qPCR experiments were performed in tech-
nical triplicate for each RNA sample. Data was analyzed
using the comparative threshold cycle (CT) method with
GAPDH or B-ACTIN as an endogenous control. Primers
used in this study (Integrated DNA Technologies, Iowa,
USA) are listed in Supplemental Materials.
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Immunofluorescence
hESC-RPE cells grown on GFR-MG or VXF were fixed
with 4% paraformaldehyde/phosphate-buffered saline (1x
PBS) (Sigma-Aldrich) for 10 min at room temperature,
then permeabilized with 0.1% TritonX-100 (Roche, In-
dianapolis, IN, USA) in PBS for 3 min. Samples were
then incubated with primary antibody (1:40–1:1000 dilu-
tion) in blocking buffer composed of 3% bovine serum
albumin (BSA) (Sigma-Aldrich) in PBS for 90 min at
room temperature. Unconjugated primary antibodies
were washed and incubated with conjugated secondary
antibodies (1:500; Invitrogen) for 30 min in the dark at
room temperature. Cell nuclei were co-stained using
Hoechst 33342 (1:1000; Life Technologies). F-actin was
stained with Alexa-Fluor-488-conjugated Phalloidin
(Phalloidin-488) (1:40; Life Technologies) for 30 min in
the dark at room temperature. Images were captured
using a Nikon C1 Confocal microscope (Nikon Instru-
ments Inc., Melville, NY, USA). Primary and secondary
antibodies used in this study are listed in Supplemental
Materials.
Flow cytometry
Dissociated cells were fixed in 4% paraformaldehyde in
PBS, centrifuged (4 °C, 300 g, 5 min), and washed in
staining medium (PBS/2% XFSR). For intracellular
marker studies, samples were permeabilized with 0.2%
Triton X-100/PBS and washed as described above. Cells
(~ 106) were resuspended in staining medium containing
fluorochrome-conjugated primary antibody or isotype
control antibody for 30 min at 4 °C. Cells were washed
three times in staining medium (4 °C, 300 g, 5 min). Un-
conjugated primary antibodies were stained with
fluorochrome-conjugated secondary antibodies for 30
min at 4 °C and washed as described above. Labeled cells
were analyzed using a FACSVERSE™ flow cytometer
(Becton Dickinson Biosciences, Franklin Lakes, NJ,
USA). Data analysis was performed using the FlowJo®
software package (Ashland, OR, USA). Primary, second-
ary, and isotype-control antibodies used in this study are
listed in Supplemental Materials (Table S2).
Scanning electron microscopy (SEM)
hESC-RPE cells cultured on GFR-MG were washed
twice with PBS and fixed in 3% glutaraldehyde (Sigma-
Aldrich) in PBS for 24 h and then dehydrated through
increasing concentrations of ethanol in PBS (25%, 45%,
55%, 65%, 75%, 85%, 90%, 95%, and 100%), followed by
rinsing twice with hexamethyldisilazane (HMDS, Sigma-
Aldrich). Samples were air-dried overnight and mounted
on aluminum stubs and gold-coated using a gold-coater
sputter (Jeol, Tokyo, Japan). Images were captured with
a Neoscope JCM-5000 (Jeol) bench-top scanning elec-
tron microscope.
Transepithelial electrical resistance (TEER)
hESC-RPE cells were seeded at 1.5 × 105 cells/cm2 onto
PET Transwell® membranes (Corning) coated with GFR-
MG and cultured for 6 weeks in XFD-RMM (Table S1).
Weekly TEER values (Ω•cm2) were obtained using an
STX2 electrode (World Precision Instruments, Sarasota,
FL, USA) from 3 replicate cultures each measured in
triplicate. Background resistance was measured in tripli-
cate equivalent wells containing no cells. Final values
were obtained by subtracting background resistance
from cell culture readings.
Cytokine ELISA
The polarized secretion of vascular endothelial growth
factor-A (VEGF-A) and pigment epithelium-derived fac-
tor (PEDF) from mature hESC-RPE cells was determined
by ELISA. Briefly, medium from the apical and basal
compartments of hESC-RPE cells cultured in Transwells
was collected after 48 h from triplicate culture wells. The
concentrations of VEGF-A and PEDF were determined
using the human VEGF-A ELISA Kit (Boster Biological
Technologies Ltd., Pleasanton, CA, USA) and human
PEDF ELISA Kit (Wuhan EIab Science Ltd., Wuhan,
China) with a microplate reader (Modulus™ II Micro-
plate Multimode Reader; Turner Biosystems, Sunnyvale,
CA, USA), according to manufacturer’s instructions.
Phagocytosis
The procedure to measure receptor-mediated phagocyt-
osis of hESC-RPE cells in cultures was adapted from a
previous study [30]. Briefly, 1-μm fluorescent micro-
spheres (Invitrogen) were incubated with VXF (5 μg/ml)
in 20mM HEPES binding buffer (Thermo Fisher Scien-
tific) for 1 h at 37 °C. The reaction was then blocked
with 0.1% BSA in HEPES binding buffer for 1 h at 37 °C.
Controls were fluorescent microspheres treated with
HEPES binding buffer containing 0.1% BSA for 2 h. Ma-
ture hESC-RPE cells were then incubated with 106
spheres per cell and cultured for 24 h at 37 °C. Excess
beads were removed by washing 5 times in PBS. Nuclei
were stained using Hoechst 33342 (1:1000). Imaging was
performed using an EVOS FL microscope (Thermo
Fisher Scientific). To confirm internalization of micro-
spheres, samples were fixed for 10 min in 4% parafor-
maldehyde in PBS, rinsed three times in PBS, followed
by nuclear staining with Hoechst 33342 and F-Actin
staining with Alexa-Fluor-488-conjugated Phalloidin (1:
40) for 30 mins in the dark at room temperature. Images
were taken using a Nikon C1 Confocal microscope.
Karyotypic analysis
Karyotype analysis of Passage 11 hESC-RPE cells was
performed by a commercial genotyping service (Sullivan
Nicolaides Pathology, Brisbane, QLD, Australia). G-band
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analysis (> 40 metaphase spreads) was performed at a
resolution of at least 400 bands per haploid set.
Statistical analyses
Biological replicates were expressed as mean ± standard
deviation (S.D). Significance was assessed using the Stu-
dent’s two-sided t test (p = 0.05).
Results
Differentiation of hESCs to hESC-RPE cells
Initially, RPE cell differentiation from the MEL-1 hESC
line was confirmed using protocols adapted from previ-
ous studies. Briefly, hESCs were cultured as embryoid
bodies in the presence of SB and CKI-7 [26, 31], with
and without NIC [25, 26, 31] (Fig. S1a). By day 5, pluri-
potent markers (OCT4 and SSEA4) were downregulated
and early retinal lineage markers (PAX6 and RAX) were
upregulated under both conditions. However, marker
changes occurred earlier and at higher levels in the
presence of NIC (Fig. S1b) [20–22]. Culture of cells from
day 6 to day 32 in the absence of factors resulted in the
appearance of foci containing cells with early RPE
morphology, with approximately 3-fold more foci in the
presence of NIC (Fig. S1c, d). These data indicate that
the MEL-1 line is not defective for RPE differentiation
using established methods [31] and that differentiation
can be enhanced by early exposure to NIC [25].
To confirm hESC-RPE cell identity, day 21 foci were
manually selected, dissociated, and replated in BDM
alongside fetal RPE controls showing classical RPE
morphology after 1 week [32] (Fig. S1e & f). By day 32,
both cultures formed RPE fluid-filled domes [33] (Fig.
S1g), and hESC-RPE cell cultures expressed RPE65 and
ZO-1 consistent with previous studies [33, 34] (Fig.
S1h), and forming apical microvilli by day 36 (Fig. S1i).
These data confirm that morphology is a useful and
non-invasive tool to quantify early stage RPE differenti-
ation in culture, supported by the subsequent expression
Fig. 1 A schematic representation for differentiation of PSCs towards retinal cells. a Known signaling pathways and regulators in the
differentiation of PSCs to RPE cells (RPECs) and neural retinal progenitor cells (NRPCs) via formation of a common eyefield progenitor cell (EFPC).
b List of small molecules for development of a differentiation protocol as substitute endogenous signals: antagonists (blue), agonists (orange). c
Timeline for in vitro differentiation of hESC-RPE cells. d Schematic showing stages in hESC differentiation. Stage 1: initiation of differentiation
under adherent or 2D conditions. Stage 2: 3D aggregation of differentiating cells forming embryoid bodies. Stage 3: continued differentiation
through plating cell bodies for outgrowth of differentiating cells. Stage 4: maturation of RPE cells with identification of cells through morphology
and marker expression. Stage 5: optimization of the differentiation protocol through body size, timing of signaling switch and time of plating.
Stage 6: characterization of differentiation through gene expression and cell functionality
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of RPE markers and mature cell characteristics at later
stages.
High efficiency of small molecule-directed hESC-RPE cell
differentiation
In developing a model for RPE differentiation, we hy-
pothesized that efficient hESC-RPE cell differentiation
could be achieved by mimicking key RPE developmental
pathways using small molecules (Fig. 1a). RPE develop-
ment involves two major steps: differentiation of pluri-
potent cells to the anterior neural ectoderm (ANE)/
eyefield (EF), followed by specification of EF cells to the
RPE [35]. In a two-stage differentiation model, hESCs
were first differentiated using inhibition of dual SMAD
signaling (SB and LDN) [36] and WNT (CKI ± NIC) to
generate ANE/EF cells [31, 37] (Fig. 1b, c), followed by
activation of Activin (IDE) [38] and WNT signaling
pathways (CHIR) [39] (Fig. 1b). To minimize the effects
of limited diffusion within aggregates, primary differenti-
ation was initiated under 2D conditions for 2 days prior
to formation of 3D aggregates (Fig. 1d). For secondary
differentiation, ANE bodies (ANEBs) were plated as ag-
gregates to minimize the effects of seeding density on
RPE differentiation efficiencies [40] (Fig. 1d).
hESC-RPE cells emerged between days 8 and 12 in all
cultures treated with SB/LDN/CKI ± NIC (primary)
followed by CHIR or CHIR/IDE, but not IDE alone (sec-
ondary) (Fig. S2a). Consistent with early experiments
and previous studies, the use of NIC during primary dif-
ferentiation enhanced final RPE cell differentiation (Fig.
S2b). Continued suspension culture of ANEBs in the ab-
sence of CHIR after day 14 resulted in clusters of heavily
pigmented cells with identifiable melanosomes by 4
weeks (Fig. S2c). These results suggest that the two-
stage small molecule differentiation protocol can result
in higher levels of hESC-RPE cell differentiation by day
14.
Small molecule exclusion reveals optimal requirements
for efficient differentiation
To gain greater insight into hESC-RPE cell differenti-
ation, we investigated the contribution of small mole-
cules to the process through systematic exclusion
(Fig. 2a, b). Since previous studies have used NIC for
prolonged periods during RPE differentiation [25, 41],
we also tested the effects of NIC during secondary differ-
entiation. At day 14, the early hESC-RPE cell morph-
ology was measured in ANEB outgrowths as a
proportion of total cells (Fig. 2b).
Across all secondary differentiation conditions, final
differentiation outcomes were relatively higher in out-
growths generated from SB/LDB/CKI/NIC (primary dif-
ferentiation) ANEBS (Fig. 2b). As expected, exclusion of
LDN in primary differentiation resulted in the complete
loss of hESC-RPE cells under most secondary differenti-
ation conditions (Fig. 2b), while exclusion of CKI and/or
NIC in primary differentiation reduced differentiation by
day 14 (Fig. 2b). With respect to secondary conditions,
the exclusion of CHIR resulted in the greatest decrease
in final RPE differentiation levels. While IDE alone did
not enhance final RPE differentiation, the combination
of CHIR/IDE resulted in more robust differentiation
relative to all primary conditions. Unexpectedly, we
found that the addition of NIC during secondary differ-
entiation had a negative effect on hESC-RPE cell differ-
entiation (Fig. 2b). The optimal signaling strategy for
hESC-RPE cell differentiation (SB/LDN/CKI/NIC + IDE/
CHIR) resulted in outgrowths, comprised almost entirely
of hESC-RPE cells (Fig. 2c).
Cells differentiated under optimal primary and second-
ary conditions were cultured without factors between
days 14 and 28. The absence of factors between days 14
and 28 gave rise to pigmented, polygonal cells (Fig. 2c)
that stained for early RPE markers (OTX2, MITF,
PMEL17) and for late RPE markers (CRALBP, RPE65)
(Fig. 2d). Weak apical staining of MTC-1 and ZO-1 at
tight junctions suggested incomplete maturation (Fig. 2e).
Taken together, these data support our signaling model
for hESC-RPE differentiation within 2 weeks.
A protocol for efficient reproducible differentiation
Repeated differentiation experiments on Matrigel re-
sulted in reproducible and consistent morphologies at
distinct timepoints (Fig. 3a). Reproducibility of differen-
tiation was also reflected in gene expression analysis
measured by qPCR between days 0 and 14. Transcrip-
tional changes during this time revealed stepwise hESC-
RPE cell differentiation via ANE/EF cell intermediates
(Fig. 3b). In particular, the partial (~ 50%) downregula-
tion of OCT4 by day 4, combined with upregulation of
PAX6(−5a) (retinal specific gene splice form) and LHX2,
plus the transient upregulation of RAX between days 4
and 6, is consistent with eyefield differentiation [42, 43]
(Fig. 3b). The developmental competence of ANE/EF
cells in day 6 cultures was further confirmed through
photoreceptor differentiation under alternative second-
ary conditions, resulting in rhodopsin+/recoverin+ cells
by day 21 (unpublished data). Upregulation of MITF and
PMEL17 between days 10 and 14 indicated RPE differen-
tiation, while upregulation of VSX2 indicates some non-
specific differentiation to the neural retinal lineage
(Fig. 3b). These data indicate that RPE differentiation
has occurred via an anterior neuroectodermal/eyefield
fate in our system.
Finally, we quantified hESC-RPE cell differentiation ef-
ficiencies at day 14 using samples from the triplicate ex-
periments used for gene expression analysis. hESC
cultures expressed TRA-1-81 (98.6% ± 0.2%), but very
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little MITF (2.1% ± 0.9%) or PMEL17 (0.8% ± 0.3%)
(Fig. 3c). At day 14, TRA-1-81 was downregulated (0.5 ±
0.11%), while a high proportion of cells were positive for
MITF (89.7 ± 1.44%, n = 3) and PMEL17 (90.1 ± 5.9%,
n = 3) (Fig. 3c).
We then adapted the protocol to complete xeno-free/
defined conditions to demonstrate the potential for clin-
ical application. All reagents remained the same except
for the use of the human recombinant substrate VXF to
replace Matrigel. Prior to differentiation, hESCs were
Fig. 2 Optimization of differentiation by small molecule exclusion assay. The procedure for plating cells, managing embryoid bodies, and then
replating cells was optimized to obtain maximal outgrowth of differentiated cells by 14 days. a Schematic of cell differentiation, including details
of physical manipulation, timing, substrate, medium and signaling. b Schematic of different factors and their combinations to develop an
optimized differentiation protocol. (+) present, (−) absent, (+/−) days 7–9, (−/+) days 10–14. Morphological analysis was used to calculate
outgrowth of cells with early RPE morphology as percentage of total cells. NFC no factor controls. c Cells grown under the best small molecule
conditions of CKI/LDN/SB/NIC (primary) followed by CHIR/ IDE (secondary). A representative body is shown at day 16 with contours demarcating
zones of cells with different morphology. Scale = 1000 μm. The green zone identifies cells with classical RPE cell morphology, the red zone
demarcates outgrowth of more fibroblastic cells and the blue zone shows the leading edge of the body (i, ii). Phase contrast microscopy shows
cells at day 16 in the green zone with typical early RPE cell morphology (iii). Scale = 50 μm. SEM shows immature hESC-RPE cells without
microvilli (iv). Scale = 2 μm. d After 28 days of growth, cell monolayers under phase microscopy reflect uniformly pigmented, polygonal RPE cells.
Scale = 200 μm. e Differential interference contrast (DIC) microscopy shows dark pigmentation of in vitro matured hESC-RPE cells.
Immunofluorescent staining shows expression of key RPE cell transcription factors (OTX2 and MITF), pre-melanocyte marker (PMEL17), visual cycle
proteins (CRALBP and RPE65), and mature RPE cell markers (MCT-1 and ZO-1). Phalloidin stained F-actin identifies cell boundaries. Hoescht33342
was used to stain nuclei. Scale = 50 μm
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adapted to mTeSR-E8 and cultured on Vitronectin-XF
(Fig. S3 a, b) and then differentiated under previously
optimized conditions. Consistent with our previous data,
day 14 ANEB outgrowths contained high proportions of
cells with early hESC-RPE cell morphology (Fig. S3c).
Quantification of differentiation efficiencies by flow cy-
tometric analysis showed PMEL17 expression in ~ 85%
of cells (Fig. S3d). Continued culture from day 14 to day
28 in XFD-BDM resulted in ANEB outgrowths with
lightly pigmented, cobblestone monolayers (Fig. S3e)
and several fluid-filled domes (not shown). Immuno-
fluorescence at day 28 showed cytoplasmic expression of
PMEL17, with ZO-1 expression localized at tight junc-
tions (Fig. S3f). Overall, these data demonstrate the
Fig. 3 Evidence of in vitro differentiation. a Phase contrast microscopy shows key morphological changes: Human embryonic stem cell (hESC:
MEL-1 line) morphology prior to differentiation, formation of differentiating cell monolayers (day 2), and anterior neuroectoderm bodies (ANEBs)
(day 5). Plated ANEBs produce expanding sheets of hESC-RPE cell monolayers in the outgrowth by day 14. Scale = 100 μm. b Gene expression
over the 14-day differentiation period was measured by qPCR in relation to GAPDH and normalized to maximum expression for each gene over
the time period. Normalized expression profiles indicate loss of hESCs (OCT4), upregulation of neuroectoderm [PAX6(+5a), PAX6(−5a), and LHX2],
eyefield formation (RAX), and differentiation of RPE cells (MITF and PMEL17). Contaminating neural retinal cell formation was monitored through
expression of VSX2. Series A, B, C reflect independent time course experiments and data points reflect the average of technical triplicates. c Flow
cytometry indicates expression of TRA-1-81, MITF, and PMEL17 by hESCs at day 0, and differentiation hESC-RPE (ANEBs) at day 14. Data reflect
mean + S.D. (n = 3). For each marker, significant differences are detected in the staining of hESCs versus day 14 ANEBs (p < 0.0001)
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simple adaptation of hESC-RPE cell differentiation to
xeno-free/defined conditions by changing the substrate
from Matrigel to Vitronectin-XF.
Taken together, these data confirm the robust differ-
entiation of hESC-RPE cells along known developmental
cell fates at high efficiency and can be translated to a
GMP (Good Manufacturing Practice) process with min-
imal changes in reagents.
Stability of expanded hESC-RPE cells
RPE cells have limited potential for in vitro expansion
and lose markers of cell fate over extended culture [24].
We therefore investigated the ability of hESC-RPE cells
to maintain RPE markers after prolonged expansion.
Flow cytometry showed maintenance of RPE (OTX2,
MITF, PMEL17, and CRALBP) and proliferation (Ki67)
markers at passage 8 (Fig. 4a). The lack of detectable
TRA-1-81 expression indicated the absence of dediffer-
entiated cells or the persistence of pluripotent cells in
long-term cultures. Furthermore, karyotypic analysis at
passage 11 showed cells retained a normal karyotype
(Fig. 4b). No evidence of epithelial-to-mesenchymal
transition was seen by passage 11.
Further analysis of hESC-RPE cell maturation by qRT-
PCR showed distinct differences in the expression of
early and late RPE genes between immature (day 14)
and mature (P6) hESC-RPE cells (Fig. 4c). Compared to
immature cells, mature cells showed downregulation of
the early retinal differentiation marker (PAX6), mainten-
ance of RPE fate genes (MITF), and upregulation of
genes required for RPE function, pigmentation
(PMEL17), the visual cycle (BEST-1, RPE65), cytokine
production (PEDF, VEGF-A), and tight junction forma-
tion (CLDN19) (Fig. 4c). The gene expression data indi-
cated hESC-RPE cell maturation at the transcriptional
level. Further evidence of maturation could also be seen
in the re-pigmentation of cells and the development of
apical microvilli (Fig. 4d, e). Finally, immunofluorescence
Fig. 4 Cultured hESC-RPE cells maintain identity following expansion. a Flow cytometric analysis of RPE markers (OTX2, MITF, PMEL17, and
CRABLP), the proliferation marker (Ki67) and pluripotent hESC marker (TRA-1-81) in sub-confluent, actively dividing cells in hESC-RPE cell cultures.
b Karyotypic analysis of hESC-RPE cells at passage 11. c Gene expression analysis comparing immature hESC-RPE (I-hESC-RPE) cells with maturing
hESC-RPE (M-hESC-RPE) cells expressed relative to human fetal RPE cells. d Re-acquisition of pigmented, cobblestone morphology in hESC-RPE
cell monolayers after 4 weeks under optimized maturation conditions. Scale = 100 μm. e Scanning electron microscopic images of mature hESC-
RPE cells with developed apical microvilli. Scale = (top) 100 μm, (bottom) 2 μm. f Confocal immunofluorescent detection of MITF, PMEL17, ZO-1,
RPE65, CRALBP, and MERTK in matured hESC-RPE cell monolayers
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from antibody staining showed highly uniform expres-
sion of key RPE markers (MITF, PMEL17, ZO-1, RPE65,
CRALBP, and MERTK) (Fig. 4e).
In vitro function of mature hESC-RPE cells on PET
membranes
The literature suggests that an optimal cell therapy for
AMD is a mature, polarized monolayer of hPSC-RPE
cells delivered on a supportive scaffold [20]. We there-
fore created a prototype implant similar to that used in
human clinical studies [44] in order to study maturation
and function of cells grown on a membrane in vitro.
Passage 11 hESC-RPE cells were seeded on polyethylene
(PET) Transwell membranes in xeno-free/defined retinal
maturation media (XFD-RMM: Table S1) and character-
ized at various timepoints. Photomicroscopy at day 28
revealed the formation of homogeneous RPE monolayer
reminiscent of the polarized native epithelium, with
well-organized cobblestone architecture and pigmenta-
tion (Fig. 5a, b). Monolayers expressed F-ACTIN and
MCT-1 localized to tight junctions and apical microvilli,
respectively (Fig. 5c).
Mature hESC-RPE cell monolayers were then tested
for critical functions of the native RPE. Phagocytosis of
photoreceptor outer segments is a highly specific func-
tion of RPE cells mediated in part via the vitronectin re-
ceptor αvβ5 which is required for outer segment
phagocytosis [45]. Following 24-h exposure, hESC-RPE
cell monolayers showed preferential binding and uptake
of vitronectin-coated beads compared to BSA controls
(Fig. 5d). Transepithelial electrical resistance (was mea-
sured to test barrier function across week 1 through
week 6. TEER values steadily rose until week 4 (~ 400Ω
× cm2) and remained constant through to week 6
(Fig. 5e). Finally, hESC-RPE cell monolayers secreted
PEDF and VEGF-A in a polarized manner and at
Fig. 5 Mature cell characteristics. a Mature hESC-RPE cells grown on PET membranes at day 28. b Fluorescent detection of F-actin (phalloidin) on
mature hESC-RPE monolayers (left) with DIC photomicroscopy (right). Scale = 100 μm. c Confocal Z-stack analysis of F-actin (Phalloidin) and MCT-1
in mature hESC-RPE monolayers. Scale = 50 μm. d Uptake of fluorescent beads coated with VXF or BSA (control) demonstrate receptor-mediated
phagocytosis. Scale = 400 μm. Z-stack confocal microscopy shows internalization of beads, shown below cell membranes. Phalloidin staining of F-
actin (green) shows apical membrane of hESC-RPE cells. Scale = 15 μm). e Measurement of transepithelial electrical resistance (TEER) over 6 weeks
(n = 4). f Directional secretion of VEGF and PEDF from mature hESC-RPE cells (n = 3)
Limnios et al. Stem Cell Research & Therapy          (2021) 12:248 Page 10 of 14
physiologically relevant levels, consistent with normal
RPE function (Fig. 5f).
Taken together, these data suggest that methods devel-
oped here for generation, expansion, and maturation of
hESC-RPE cells result in phenotypically and functionally
stable cells that maintain the functional properties of the
native RPE required for cell therapy up to at least 11
passages.
Discussion
The clinical translation of hPSC technology promises to
transform the treatment of AMD over the coming dec-
ade. To date, the production of hPSC-RPE cells for use
in human trials has mostly depended on spontaneous
differentiation [20]. However, treatment of large patient
numbers will require much more efficient differentiation
protocols to generate large numbers of homogeneous
functional cells that cannot easily be generated by the
protocols used for clinical trials to date. In this study, we
have developed a rapid directed protocol to generate
hESC-RPE cells at high efficiency using small molecules,
under feeder-free, xeno-free, and chemically defined
conditions.
The efficiency of our protocol was shown to be con-
sistently high and reproducible, indicating the robustness
of the method. While the differentiation efficiencies ob-
tained here are similar to previous studies [28, 29], we
show fast and efficient differentiation in the complete
absence of cytokines and under xeno-free/defined condi-
tions. Other studies working towards clinical grade cell
production have claimed high efficiencies using XFD
media and substrates; however, they did not show sub-
jective measures of differentiation efficiency prior to pas-
sage and expansion [46]. Similarly, a recent method by
Regent et al. (2019) describes a differentiation process
achieved with the sequential use of three factors (Nicoti-
nimide, Activin A, and CHIR99021). However, this
method requires a 6-week process and no data on yield
was provided immediately after differentiation and prior
to dissociation-based selection [47].
Our signaling model for in vitro RPE cell differenti-
ation is based on the sequence of signals that drive pluri-
potent cells of the human blastocyst to the eyefield and,
subsequently, the RPE. Small molecule inhibition of the
dual SMAD pathways (SB/LDN) and WNT signaling
pathways (CKI) follows a highly conserved developmen-
tal mechanism [48, 49] and is consistent with both the
“default” model [50] and the “active” model of anterior
neural differentiation [51]. As in previous studies, we
found dual SMAD inhibition was necessary for efficient
neural induction within a week [36, 37, 46], while WNT
inhibition [44] and NIC were required for the anterior
specification of neuroectoderm to form the eyefield.
The timing of differentiation from the eyefield to early
RPE cells is in accordance with the development of the
optic primordium (eyefield) at Carnegie Stage 10 (day
22) [52] and the first appearance of melanin granules in
the RPE at stage 13 (day 32) [53], which is approximately
10 days. Our protocol is also similar to previous in vitro
studies showing efficient RPE differentiation from hESCs
by 14 days [28], suggesting that the rate of differentiation
in our system is highly similar to both in vivo and
in vitro development of RPE cells.
WNT inhibition with CKI and NIC were both required
during primary differentiation (days 0–6) for optimal dif-
ferentiation by day 14, indicating an additive effect of
both via a common target. Although NIC has been used
in several hESC-RPE cell differentiation protocols [25,
28, 29, 41], the proposed mechanism of activity was pre-
viously attributed to increased cell survival during neural
differentiation [28, 41]. However, in this study, we noted
higher levels of cell death under conditions using NIC
(Fig. 2b). A recent study identified a possible mechanism
for the redundancy of NIC, which we note here, involv-
ing a role for NIC in inhibition of casine kinase 1 [54],
also consistent with our differentiation model.
Secondary differentiation was primarily dependent on
WNT activation using CHIR and is consistent with spe-
cification of the eyefield to the RPE via activation of
MITF [42, 55, 56]. For any given primary differentiation
condition, secondary differentiation with IDE resulted in
higher consistency of final RPE differentiation, but at
lower efficiency than CHIR alone. Optimal differenti-
ation required the combined use of both CHIR and IDE.
Since IDE does not fully mimic the Activin-like signaling
required for RPE development using Activin A, this find-
ing will require further investigation.
The addition of NIC during secondary differentiation
lowered final differentiation outcomes when used in
combination with CHIR and IDE, consistent with its
proposed role in inhibition of WNT signaling via inhib-
ition of casine kinase 1 [54]. These findings suggest that
existing protocols using NIC may benefit from the delib-
erate exclusion of NIC after the eyefield stage [25, 41].
Gene expression profiling across day 0 to day 14 re-
vealed that hESC-RPE cell differentiation occurs via a de-
fined intermediate population with characteristic
expression of eyefield markers [28]. This is consistent with
the existence of a multipotent eyefield progenitor cell
(EFPC) as shown in Fig. 1. This differentiation model can
then be as a basis to generate and identify an EFPC and to
divert differentiation along the neural retinal lineage, with
possible generation of photoreceptors or ganglion cells.
Consistent with this hypothesis, our own experiments
have found that differentiating hESCs are competent to
form either RPE cells or photoreceptors depending on
treatment after primary differentiation (unpublished data).
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Mature hESC-RPE cells generated in this study form
homogeneous polarized monolayers in culture dishes
and when grown on a planar membrane, such that cells
retain key morphological, molecular, and functional hall-
marks of the native RPE. After cryopreservation and fur-
ther expansion to passage 11, hESC-RPE cells retained
the ability to form highly homogeneous monolayers of
polarized epithelium, while maintaining RPE marker ex-
pression and function need for cell therapy. These re-
sults at passage 11 are therefore significant, showing that
our cells were capable of reaching molecular and func-
tional maturity after expansion and cryopreservation,
which is an important consideration in view of clinical
and commercial scale production and storage.
Oncogenic transformation of cells is a concern when
cells are intended for human therapy. We have observed
no unusual cell growth during tissue culture, but instead,
routinely see contact inhibition in hESC-RPE cells upon
reaching confluence. In the course of this work, we have
also conducted in vivo transplantation studies into
vision-impaired pigmented RCS-p (Royal College of Sur-
geons) rats and can report an absence of tumor forma-
tion at 1 month post-transplantation of cells into the
sub-retinal space (data in preparation). However, the
safety of hESC-RPE cells will need to be established
leading up to clinical trial and this will require high
coverage genomic sequencing as well as extensive gene
expression studies to identify any changes in the genome
or expression of tumor and anti-apoptotic genes. Such a
detailed study is anticipated ahead of production of
GMP-grade cells for pre-clinical and clinical studies
similar to those carried out in other pre-clinical studies
[57].
Conclusion
The hESC-RPE cell differentiation protocol presented in
this study addresses the need for efficiency under xeno-
free/defined conditions. Adaptation of the protocol to a
strictly 2D adherent format represents a critical step to-
wards a manufacturing process. To date, the procedure
has been applied to three distinct hESC lines and is
under test on hIPSC lines. The method forms the
ground work for development of a robotic manufactur-
ing process to generate cells for banking and later
transplantation.
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